PT1796668E - Preparação farmacêutica aquosa compreendendo roflumilast - Google Patents
Preparação farmacêutica aquosa compreendendo roflumilast Download PDFInfo
- Publication number
- PT1796668E PT1796668E PT05794694T PT05794694T PT1796668E PT 1796668 E PT1796668 E PT 1796668E PT 05794694 T PT05794694 T PT 05794694T PT 05794694 T PT05794694 T PT 05794694T PT 1796668 E PT1796668 E PT 1796668E
- Authority
- PT
- Portugal
- Prior art keywords
- pharmaceutical preparation
- roflumilast
- aqueous pharmaceutical
- administration
- aqueous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Farming Of Fish And Shellfish (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004046235A DE102004046235A1 (de) | 2004-09-22 | 2004-09-22 | Arzneimittelzubereitung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1796668E true PT1796668E (pt) | 2008-12-22 |
Family
ID=35447576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05794694T PT1796668E (pt) | 2004-09-22 | 2005-09-21 | Preparação farmacêutica aquosa compreendendo roflumilast |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9205044B2 (pt) |
| EP (1) | EP1796668B1 (pt) |
| JP (1) | JP5044404B2 (pt) |
| AT (1) | ATE408405T1 (pt) |
| AU (1) | AU2005286476B2 (pt) |
| CA (1) | CA2580397C (pt) |
| CY (1) | CY1109407T1 (pt) |
| DE (2) | DE102004046235A1 (pt) |
| DK (1) | DK1796668T3 (pt) |
| ES (1) | ES2314718T3 (pt) |
| HR (1) | HRP20080640T3 (pt) |
| ME (1) | ME01050B (pt) |
| PL (1) | PL1796668T3 (pt) |
| PT (1) | PT1796668E (pt) |
| RS (1) | RS50641B (pt) |
| SI (1) | SI1796668T1 (pt) |
| WO (1) | WO2006032675A1 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| BRPI0918253A2 (pt) * | 2008-09-12 | 2015-12-15 | Critical Pharmaceuticals Ltd | aperfeicoamento na absorcao de agentes terapeuticos atraves das membranas mucosas ou da pele |
| EA034552B1 (ru) | 2009-05-11 | 2020-02-19 | БЕРГ ЭлЭлСи | Способ лечения или предотвращения прогрессирования онкологических заболеваний |
| GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
| PE20130045A1 (es) | 2010-03-12 | 2013-01-28 | Berg Pharma Llc | FORMULACIONES INTRAVENOSAS DE COENZIMA Q10 (CoQ10) Y METODOS DE USO DE LAS MISMAS |
| JP2014511393A (ja) * | 2011-03-07 | 2014-05-15 | セルジーン コーポレイション | イソインドリン化合物を用いた疾患の治療方法 |
| ES2762451T3 (es) | 2011-04-04 | 2020-05-25 | Berg Llc | Tratamiento de tumores del sistema nervioso central con coenzima Q10 |
| CN102793684B (zh) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | 罗氟司特液体制剂及其制备方法 |
| KR102058256B1 (ko) | 2011-06-17 | 2020-01-22 | 버그 엘엘씨 | 흡입성 약제학적 조성물들 |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| JP6731336B2 (ja) | 2013-04-08 | 2020-07-29 | バーグ エルエルシー | コエンザイムｑ１０併用療法を用いた癌の処置方法 |
| TW201540301A (zh) | 2013-08-16 | 2015-11-01 | Takeda Gmbh | 以ｐｄｅ４抑制劑治療認知損傷 |
| WO2015035094A1 (en) | 2013-09-04 | 2015-03-12 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
| CN105287366B (zh) * | 2014-06-18 | 2018-02-16 | 张蕊 | 一种维生素k1注射液及其制备方法 |
| US9969688B2 (en) | 2014-10-24 | 2018-05-15 | Hisamitsu Pharmaceutical Co., Inc. | Roflumilast prodrugs |
| JP6962655B2 (ja) * | 2015-07-07 | 2021-11-05 | ライフラフト バイオサイエンシーズ，インコーポレイテッド | 低ナトリウムポロキサマー１８８製剤および使用方法 |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| AU2019281888B2 (en) | 2018-06-04 | 2024-05-02 | Arcutis Biotherapeutics, Inc. | Method and formulation for improving roflumilast skin penetration lag time |
| KR102117525B1 (ko) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물 |
| AU2021214399A1 (en) | 2020-01-31 | 2022-08-25 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half-life |
| JPWO2021157569A1 (pt) * | 2020-02-03 | 2021-08-12 | ||
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| MX2023009352A (es) | 2021-02-10 | 2023-08-16 | Iolyx Therapeutics Inc | Metodos para la administracion oftalmica de roflumilast. |
| WO2024058848A1 (en) | 2022-09-15 | 2024-03-21 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0706513T1 (en) | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| ATE375803T1 (de) * | 1998-05-07 | 2007-11-15 | Corixa Corp | Adjuvanszusammensetzung und methoden zu deren verwendng |
| ATE279924T1 (de) | 1999-03-10 | 2004-11-15 | Altana Pharma Ag | 3-cyclopropylmethoxy-4-difluormethoxy-n-(3,5- dichlor-pyrid-4-yl)-benzamid zur behandlung von multipler sklerose |
| US20020193393A1 (en) * | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ATE417628T1 (de) * | 2002-05-28 | 2009-01-15 | Nycomed Gmbh | Topisch anwendbare pharmazeutische zubereitung |
| US20030235631A1 (en) * | 2002-06-17 | 2003-12-25 | Pfizer Inc. | Combination treatment for depression and anxiety |
| US20040058950A1 (en) * | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040136990A1 (en) * | 2002-07-19 | 2004-07-15 | Abbott Biotechnology Ltd. | Treatment of pain using TNFalpha inhibitors |
-
2004
- 2004-09-22 DE DE102004046235A patent/DE102004046235A1/de not_active Withdrawn
-
2005
- 2005-09-21 AU AU2005286476A patent/AU2005286476B2/en not_active Ceased
- 2005-09-21 PL PL05794694T patent/PL1796668T3/pl unknown
- 2005-09-21 ES ES05794694T patent/ES2314718T3/es active Active
- 2005-09-21 WO PCT/EP2005/054723 patent/WO2006032675A1/en active Application Filing
- 2005-09-21 DK DK05794694T patent/DK1796668T3/da active
- 2005-09-21 AT AT05794694T patent/ATE408405T1/de active
- 2005-09-21 CA CA2580397A patent/CA2580397C/en not_active Expired - Fee Related
- 2005-09-21 SI SI200530511T patent/SI1796668T1/sl unknown
- 2005-09-21 US US11/662,887 patent/US9205044B2/en not_active Expired - Fee Related
- 2005-09-21 RS RSP-2008/0591A patent/RS50641B/sr unknown
- 2005-09-21 DE DE602005009848T patent/DE602005009848D1/de active Active
- 2005-09-21 PT PT05794694T patent/PT1796668E/pt unknown
- 2005-09-21 JP JP2007531767A patent/JP5044404B2/ja not_active Expired - Fee Related
- 2005-09-21 EP EP05794694A patent/EP1796668B1/en active Active
- 2005-09-21 ME MEP-2008-797A patent/ME01050B/me unknown
-
2008
- 2008-12-09 HR HR20080640T patent/HRP20080640T3/xx unknown
- 2008-12-10 CY CY20081101429T patent/CY1109407T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE408405T1 (de) | 2008-10-15 |
| SI1796668T1 (sl) | 2009-02-28 |
| US9205044B2 (en) | 2015-12-08 |
| RS50641B (sr) | 2010-06-30 |
| WO2006032675A1 (en) | 2006-03-30 |
| AU2005286476A1 (en) | 2006-03-30 |
| EP1796668A1 (en) | 2007-06-20 |
| ES2314718T3 (es) | 2009-03-16 |
| AU2005286476B2 (en) | 2011-11-10 |
| CY1109407T1 (el) | 2014-07-02 |
| DE102004046235A1 (de) | 2006-03-30 |
| HRP20080640T3 (en) | 2009-01-31 |
| PL1796668T3 (pl) | 2009-02-27 |
| CA2580397A1 (en) | 2006-03-30 |
| ME01050B (me) | 2012-10-20 |
| EP1796668B1 (en) | 2008-09-17 |
| DE602005009848D1 (de) | 2008-10-30 |
| DK1796668T3 (da) | 2009-02-02 |
| US20070259009A1 (en) | 2007-11-08 |
| CA2580397C (en) | 2013-07-30 |
| JP2008513416A (ja) | 2008-05-01 |
| JP5044404B2 (ja) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20080640T3 (en) | Aqueous pharmaceutical preparation comprising roflumilast | |
| UA89220C2 (ru) | Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы | |
| IL179719A0 (en) | Process for preparation of amorphous form of drug | |
| WO2008063671A3 (en) | Heterobicyclic metalloprotease inhibitors | |
| HRP20050458A2 (en) | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base | |
| WO2006007448A3 (en) | Pharmaceutical co-crystal compositions and related methods of use | |
| PT1687305E (pt) | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase | |
| HK1164123A1 (en) | Unitary pharmaceutical dosage form comprising tenofovir df, emtricitabine, efavirenz and a surfactant df | |
| ZA200603538B (en) | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same | |
| WO2006044805A3 (en) | Less abusable pharmaceutical preparations | |
| DK1480679T3 (da) | Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat | |
| GEP20115222B (en) | New pharmaceutical compounds | |
| WO2004071374A3 (en) | Once a day orally administered pharmaceutical compositions | |
| MXPA05011248A (es) | Derivados de wortmanina solubles en agua. | |
| WO2005105081A3 (en) | Therapeutic formulations of desoxyepothilones | |
| WO2008020314A3 (en) | Statin stabilizing dosage formulations | |
| WO2008070495A3 (en) | Short term slow release drug delivery system | |
| AU2003260239A1 (en) | Solid dosage forms for rapid dissolution of poorly soluble drugs | |
| WO2008097539A3 (en) | Multi-modal absorption, medicine-delivery lozenge, and use thereof | |
| TW200621304A (en) | Pharmaceutical composition | |
| WO2004069228A3 (en) | Sustained release formulations of venlafaxine | |
| WO2005023223A3 (de) | Oral zu applizierende darreichungsform für schwerlösliche saure und amphotere wirkstoffe | |
| ZA200705996B (en) | Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof | |
| NO20081213L (no) | Mikropartikkelsammensetninger av topoisomerase I-inhibitoren 7-tert-butoksyiminometylcamptothecin | |
| WO2005082858A3 (en) | Isoquinoline derivatives |